Off-Label Cancer Drugs Show Durable Benefits in Large Trial
- A large-scale prospective evaluation of off-label targeted cancer therapies has found that while overall activity is modest, specific subgroups of patients can achieve meaningful and durable benefits from...
- The findings come from the Drug Rediscovery Protocol (DRUP), a trial conducted in the Netherlands.
- Between July 2016 and May 2024, the DRUP trial included 1,610 patients who were treated with 37 different off-label drugs.
A large-scale prospective evaluation of off-label targeted cancer therapies has found that while overall activity is modest, specific subgroups of patients can achieve meaningful and durable benefits from drugs approved for different types of cancer.
The findings come from the Drug Rediscovery Protocol (DRUP), a trial conducted in the Netherlands. The study focused on patients with advanced solid tumors who lacked standard treatment options but possessed actionable genomic alterations, making them candidates for drugs approved for other tumors with similar genetic profiles.
Study Scope and Patient Outcomes
Between July 2016 and May 2024, the DRUP trial included 1,610 patients who were treated with 37 different off-label drugs. Of these participants, 1,363 were evaluable for response, a group that included 533 patients, or 39.1%, with rare cancers.
The clinical benefit rate, defined as a confirmed response or stable disease for at least 16 weeks, was 34.9%. The objective response rate was recorded at 15.7%.
In terms of survival and progression, the trial reported a median progression-free survival of 3.4 months and a median overall survival of 8.2 months.
Safety data indicated that 28.4% of patients experienced treatment-related adverse events of Grade 3 or higher.
Precision Medicine and Exceptional Responders
The researchers noted that while the general activity across all tumor-drug combinations was modest, certain defined molecular subgroups and a small percentage of exceptional responders
—representing 7.0% of the group—achieved significant benefit.
This suggests that the efficacy of off-label precision medicines is highly dependent on the specific genomic drivers of the tumor rather than the primary site of the cancer.
The evidence generated through the DRUP trial has already had practical applications in healthcare policy, as the data was used by regulatory bodies in the Netherlands to make reimbursement decisions.
Frameworks for Future Off-Label Use
The study highlights a systemic gap in how off-label cancer drug use is tracked. Because outcomes are rarely captured systematically, there is a risk of repeated futile treatments and a lack of evidence-based decision-making.
To address these risks and maximize patient benefit, the researchers recommend that off-label precision medicines be administered only within structured frameworks. These frameworks should include the following components:
- Systematic evaluation of both efficacy and toxicity.
- Support for the refinement of biomarkers.
- Stepwise assessment to potentially enable future label expansion for the drugs.
- Prioritization of high-confidence targets and early intervention.
- Use of regulatory-aligned end-points and international collaboration.
By implementing these standards, the medical community can better identify which patients are likely to benefit from drug rediscovery while avoiding the administration of ineffective therapies.